Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases.
- Author:
Yakup ALBAYRAK
1
;
Kenji HASHIMOTO
Author Information
1. Department of Psychiatry, Medical Faculty, Namik Kemal University, Tekirdag, Turkey.
- Publication Type:Case Report
- Keywords:
Sigma receptor;
Fluvoxamine;
Akathisia;
Dyskinesia
- MeSH:
Akathisia, Drug-Induced*;
Dyskinesias;
Endoplasmic Reticulum;
Fluvoxamine*;
Humans;
Hyperkinesis;
Movement Disorders*;
Neurodegenerative Diseases;
Obsessive-Compulsive Disorder;
Psychomotor Agitation;
Receptors, sigma;
Schizophrenia*;
Serotonin
- From:Psychiatry Investigation
2013;10(4):417-420
- CountryRepublic of Korea
- Language:English
-
Abstract:
Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.
